NCT01615796View on ClinicalTrials.gov

Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 4, 2012

Primary Completion Date

February 21, 2014

Study Completion Date

February 21, 2014

Conditions
Infections, Respiratory Tract
Interventions
DRUG

Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined

Subjects receive a single dose of GSK2140944

DRUG

Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined

Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01615796 - Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses | Biotech Hunter | Biotech Hunter